U.S., EU and Japan Health Authorities Accept Regulatory Submissions For Review Of Pfizer ’s Third-generation ALK Inhibitor Lorlatinib

February 12, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the company ’s New Drug Application for lorlatinib. Lorlatinib is an investigational, anaplastic...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news